文献速递类风湿关节炎

数据驱动方法构建类风湿关节炎可行且反应性好的超声炎症评分

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach.
PubMed 文献 · RMD Open · 2016-12-16

研究利用早期RA队列开发、确立RA生物制剂治疗队列验证,从4肌腱36关节全评分中通过因子分析筛选出8关节1肌腱的USRA9评分。该评分在早期RA中6个月SRM为GSUS -1.24、PDUS -1.09,保留全评分87%与90%信息,验证队列中表现优于既往评分。

要点

  • USRA9评分包含双侧8关节(MCP1-3、PIP2-3、桡腕、MTP2-3)和1肌腱(尺侧腕伸肌)。
  • 早期RA中6个月SRM:GSUS -1.24(95%CI -1.47~-1.02),PDUS -1.09(-1.25~-0.92)。
  • USRA9保留全评分信息GSUS 87%、PDUS 90%,验证队列表现优于既往评分。

核心结论

  • USRA9炎症评分反应性好,保留全评分大部分信息,验证队列中总体优于既往评分。

研究设计与样本

  • 利用早期RA队列(开发)和确立RA起始/转换生物制剂治疗队列(验证)开展数据驱动评分构建与验证研究。
  • 开发队列基于3个月变化的因子分析筛选超声评分成分,验证队列评估表现。
  • 共纳入118例早期RA和212例确立RA患者。

主要发现

  • 最终评分纳入双侧8关节和1肌腱,即USRA9。
  • 早期RA 6个月SRM:GSUS -1.24(95%CI -1.47至-1.02),PDUS -1.09(-1.25至-0.92)。
  • USRA9保留全评分信息量GSUS 87%、PDUS 90%。
  • 验证队列中USRA9表现略优于既往提出的评分。

关键数值与推荐

  • USRA9检查关节:MCP1、2、3,PIP2、3,桡腕关节,MTP2、3;肌腱:尺侧腕伸肌;均双侧检查。
  • 反应性以标准化反应均值(SRM)评估,早期RA 6个月GSUS SRM -1.24、PDUS SRM -1.09。

临床怎么用

  • USRA9可作为RA超声炎症评估的可行精简评分,适用于早期RA和生物制剂治疗RA的纵向监测。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop and validate a responsive and feasible ultrasound inflammation score for rheumatoid arthritis (RA). METHODS: We used data from cohorts of early RA (development) and established RA starting/switching biologic therapy (validation). 4 tendons and 36 joints were examined by a grey scale (GSUS) and power Doppler semiquantitative ultrasound (PDUS) scoring system (full score). Ultrasound score components were selected based on factor analyses of 3-month change in the development cohort. Responsiveness was assessed by standardised response means (SRMs). We assessed the proportion of information retained from the full score by linear regression. RESULTS: 118 patients with early and 212 patients with established RA were included. The final ultrasound score included 8 joints (metacarpophalangeal 1-2-3, proximal interphalangeal 2-3, radiocarpal, metatarsophalangeal 2-3) and 1 tendon (extensor carpi ulnaris) examined bilaterally. The 6-month SRMs for the final score were -1.24 (95% CI -1.47 to -1.02) for GSUS, and -1.09 (-1.25 to -0.92) for PDUS in early RA, with 87% of total information retained for GSUS and 90% for PDUS. The new score performed somewhat better than formerly proposed scores in the validation cohort. CONCLUSIONS: The Ultrasound in Rheumatoid Arthritis 9 joint/tendon score (USRA9) inflammation score showed good responsiveness, retained most of the information from the original full score and overall performed better than previous scores in a validation cohort. TRIAL REGISTRATION NUMBERS: NCT01205854, ACTRN12610000284066; Post-results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Aga AB, Berner Hammer H, Christoffer Olsen I, et al. Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach. RMD Open. 2016. PMID: 28074154. doi:10.1136/rmdopen-2016-000325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。